U.S. Markets open in 21 mins
  • S&P Futures

    4,621.25
    +55.00 (+1.20%)
     
  • Dow Futures

    34,783.00
    +326.00 (+0.95%)
     
  • Nasdaq Futures

    16,343.25
    +192.75 (+1.19%)
     
  • Russell 2000 Futures

    2,253.70
    +56.40 (+2.57%)
     
  • Crude Oil

    67.77
    +1.59 (+2.40%)
     
  • Gold

    1,790.30
    +13.80 (+0.78%)
     
  • Silver

    22.82
    +0.00 (+0.02%)
     
  • EUR/USD

    1.1340
    +0.0001 (+0.0113%)
     
  • 10-Yr Bond

    1.4800
    +0.0370 (+2.56%)
     
  • Vix

    23.75
    +6.64 (+38.81%)
     
  • GBP/USD

    1.3344
    +0.0043 (+0.3229%)
     
  • USD/JPY

    113.0600
    -0.1200 (-0.1060%)
     
  • BTC-USD

    57,939.67
    -463.22 (-0.79%)
     
  • CMC Crypto 200

    1,479.99
    +12.06 (+0.82%)
     
  • FTSE 100

    7,159.86
    +100.41 (+1.42%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Eli Lilly, Boehringer Ingelheim Tout Heart Failure Win For Jardiance

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) have announced the topline results from the EMPEROR-Preserved Phase 3 trial of Jardiance (empagliflozin).

  • Jardiance aced the primary endpoint in a pivotal outcomes trial in heart failure patients with a preserved ejection fraction (HFpEF) with or without Type 2 diabetes.

  • Jardiance cut the composite risk of cardiovascular (CV) death or hospitalization by 25% compared with placebo, potentially adding to the drug’s current label to improve glycemic control and lower the risk of CV death in patients with Type 2 diabetes and established CV disease.

  • Meanwhile, the FDA is currently reviewing the drug to treat heart failure patients with a reduced ejection fraction (HFrEF) with or without Type 2 diabetes based on the EMPEROR-REDUCED Phase 3 study results.

  • The companies expect to present full data from the Phase 3 EMPEROR-PRESERVED study at the European Society of Cardiology annual meeting in August and plan to file for regulatory submission by the 2021 end.

  • Price Action: LLY shares are down 0.13% at $234.28 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.